Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity News readers who discuss life science current events on MedCityNews.com.
Now here’s the best of what YOU had to say:
H.R. 3000: A post-repeal appeal. “The only guarantee we have with health care is its central importance on the campaign trail going into 2012. Beneath the politics, thousands of us continue moving forward every day to advance quality improvement, patient centeredness and cost control in health care. Whether we stick with the ACA or wind up with H.R. 3000, we can all agree that reform is badly needed. Let’s just hope that in the case of the latter, we’re careful not to throw the baby out with the bathwater in the name of politics.”
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Outlook for biomedical research financing unclear, panel says. “Dealing with deficits is the key to getting capital flowing to innovators, the panel concurred. However, the uncertainty over meaningful deficit reduction and entitlement reform — in Europe, Washington and even Asia — is making that a cloudy forecast for biomedical startups.”
What’s behind Mitt Romney’s wishy-washy Medicare plan? “Romney’s plan won’t save much if any money, and he must realize it. To do that would require changes to the payment and delivery system that I’m sure Romney doesn’t have any appetite for.”
States, vendors form workgroup to up EHR/HIE adoption. “The objective of the EHR/HIE Interoperability Workgroup has been to define a single set of standardized, easy-to-implement interoperability specifications that will increase the adoption of EHRs and Health Information Exchange services.”
Dear super committee: Please end ‘pay for delay’ deals. “The deficit reduction “super committee” charged with coming up with $1.2 trillion in budget reductions over the next decade shouldn’t let this one pass. The Congressional Budget Office today estimated that ending drug industry ‘pay for delay’ deals with generic manufacturers will save the federal government over $5 billion over the next decade.”
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
